
IL-10 Autoantibodies May Drive Inflammatory Bowel Disease in a Subset of Patients
A 2026 NEJM study analyzing data from more than 4,900 people with inflammatory bowel disease found that about 3.5% carry autoantibodies that block interleukin-10, effectively removing an anti-inflammatory brake and potentially driving disease in this subset; the autoantibibody presence is linked to the HLA-DRB1*01:03 variant, suggesting possibilities for early genetic testing and more targeted, mechanism-based therapies.

